Cantor Fitzgerald Initiates Coverage of Arcutis
The firm anticipates significant sales growth for the nonsteroidal Zoryve cream in the coming years.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Is now a good time for individual investors to consider buying shares in pharmaceutical companies?
Cantor Fitzgerald has initiated coverage of Arcutis Biotherapeutics with an Overweight rating, citing strong market performance for the company's Zoryve cream. The firm projects the product could eventually reach peak sales between $2.6 billion and $3.5 billion.
Why it matters
The analysis highlights a competitive shift in the dermatology market, where Arcutis aims to challenge established treatments by leveraging a nonsteroidal profile. Cantor Fitzgerald notes that current safety restrictions on rival therapies provide Arcutis with a distinct commercial advantage.
Zoryve, a nonsteroidal, once-daily cream, reported $129.9 million in net product sales for the second quarter of 2026. This performance is currently being measured against the $48 price target set by Cantor Fitzgerald.
The players
Arcutis Biotherapeutics
A biotechnology company focused on developing and commercializing dermatological treatments.
Cantor Fitzgerald
A financial services firm that provides research and market analysis.
Incyte Corporation
A biopharmaceutical company known for producing the topical treatment Opzelura.
The details
Arcutis markets Zoryve as a once-daily, nonsteroidal topical treatment for skin conditions. By avoiding corticosteroids—hormone-based drugs often used to reduce inflammation that can carry side effects with long-term use—the company aims to secure a larger share of the market. Cantor Fitzgerald analysts suggest that the treatment's competitive profile is further bolstered by the restrictive labeling, including a boxed warning, currently associated with the rival drug Opzelura.
Timeline
2022: Start of a period encompassing seven FDA approvals for Arcutis Biotherapeutics.
June 2026: FDA approval granted for Zoryve cream 0.3 percent for children aged 2 and older.
Q2 2026: Arcutis recorded $129.9 million in net product sales.
October 15, 2026: Cantor Fitzgerald initiated coverage of Arcutis Biotherapeutics.
February 23, 2027: Targeted FDA decision date for the infant indication of Zoryve cream 0.05 percent.
The Tech Race
Arcutis is positioning Zoryve to capture market share currently held by established treatments like Incyte's Opzelura. The company's progress depends on expanding its patient demographic through ongoing clinical and regulatory efforts.
Patients currently managing skin conditions may see increased availability of Zoryve as the company scales its distribution. The potential approval for infant use in 2027 would represent the next major expansion in the treatment's accessible patient base.
The takeaway
The firm's $48 price forecast emphasizes the growth potential of nonsteroidal dermatological options in the U.S. market. Investors and clinicians should monitor the February 2027 regulatory decision for the infant-strength formulation as a primary indicator of future market penetration.
What happens next
The FDA is scheduled to issue a decision regarding the approval of Zoryve cream 0.05 percent for infants by February 23, 2027.
Further reading
For more information on the evolving landscape of dermatology research, visit the Biotech section.
Source note: This article includes information reported by Benzinga.
Live Poll
Is now a good time for individual investors to consider buying shares in pharmaceutical companies?
